Anticancer Research · 2021 · 12 citations · 31 references
MedicineOncologyPharmacologyApoptosisMetastasisMolecular OncologyApoptosis In CancerApoptosis ModulationApoptosis ResistanceApoptotic SignalingCancer Cell SignalingPharmacodynamics Of Anticancer AgentsAnti-apoptotic ProteinsApoptotic Signaling PathwaysNf-kappa B-mediated Anti-apoptotic SignalingNf-κb SignalingNuclear Factor Kappa B ActivationNuclear Factor Kappa B InhibitionNuclear Factor Kappa B SignalingSorafenib Therapy
BACKGROUND/AIM: Sorafenib, an oral multi-kinase inhibitor, has been shown to improve the outcome of patients with osteosarcoma (OS). However, the anti-OS effect and mechanism of sorafenib has not yet been fully understood. The main purpose of this study was to investigate the effect of sorafenib on apoptotic signaling and Nuclear Factor-κB (NF-κB)-mediated anti-apoptotic and metastatic potential in OS in vitro. MATERIALS AND METHODS: The effect of sorafenib on apoptotic signaling transduction, anti-apoptotic, and metastatic potential of OS U-2 cells was verified with flow cytometry, trans-well invasion/migration, and western blotting assay. RESULTS: Sorafenib induced the extrinsic and intrinsic apoptotic pathways. In addition, sorafenib reduced the invasion and migration ability of OS cells, induced NF-κB activation, and the expression of anti-apoptotic proteins and metastasis-associated proteins encoded by NF-κB target genes. CONCLUSION: Sorafenib led to stimulation of extrinsic/intrinsic apoptotic pathways and NF-κB inactivation in U-2 OS cells.
31
ESMO Symposium on Immuno-Oncology 2015 Officers and Organisation
Annals of Oncology · 2015 · 732 citations · Full text
Medicine, Immunology, Oncology +12
Giovanni Grignani, Emanuela Palmerini, Palma Dileo et al. · Annals of Oncology · 2011 · 356 citations · Full text
Medicine, Oncology, Pharmacotherapy +12
Florence Duffaud, Olivier Mir, Pascaline Boudou‐Rouquette et al. · The Lancet Oncology · 2018 · 316 citations
Medicine, Oncology, Pharmacology +13